June 29, 2017  

Indi Molecular raises $11.5M in series A to back new synthetic class in research, imaging

Indi Molecular has an impressive pedigree, having been founded in 2013 by Leroy Hood of the Institute of Systems Biology, James Heath of Caltech and diagnostics entrepreneur Albert Luderer. The Culver City, Calif.-based start up is working to develop protein catalyzed capture agents (PCCs), a novel, synthetic class of binders with antibody-like properties that are expected to have both diagnostic and therapeutic applications. Now, Indi has snagged an $11.5 million series A financing to help it create a high throughput PCC discovery platform as a laboratory research tool, as well as to advance into the clinic with PET immuno-oncology imaging alongside an undisclosed major pharma partner.

See Friday's BioWorld MedTech for more on this and many other stories.

  For more information on a risk-free subscription to BioWorld MedTech please click here.